Centers | ||
|
|
|
Edinburgh Drug Discovery | EU-OPENSCREEN | Therapeutic Accelerator Program (TAP) |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
EU-OPENSCREEN is a multinational, not-for-profit initiative, which
integrates high-capacity screening platforms and chemistry groups across
Europe. The aim of this initiative is to support individual scientists
interested in chemical biology... |
Test |
Partnerships |
Events |
Jobs |
Astra Zeneca and Broad Institute to Co-develop Antiviral and Antibacterial DrugsBroad Institute and Astrza Zeneca have entered into a two year collaboration agreement to co-develop antiviral and antibacterial drugs. Screening and target hit to lead chemistry will take place at Broad while Astra Zeneca will be responsible for... View all GSK and Yale to partner on drug discovery developmentGlaxoSmithKline (GSK) and Yale University will partner to design a new class of molecules to target disease-causing proteins. This is the latest in a string of deals between Yale’s academic researchers and global pharmaceutical companies. View all Sanofi and Weill Cornell Medical College to Discover New Drus to Treat TuberculosisSanofi has entered into a new collaboration with Dr.Carl Nathan's laboratory at Weill Cornell Medical College to screen existing compounds and develop new compounds to shorten the course of treatment of tuberculosis and increase effectiveness of... View all |
No EVENTS for listing |
No Job Posts |
